Retatrutide

Overview

What is Retatrutide and what does the research say?

Identity

Also Known As

LY3437943 • GGG Triple Agonist

Type

Acylated peptide

Length

39 amino acids

Weight

~5,000 Da

Sequence

Proprietary (Eli Lilly)

Molecular Structure

Y

Aib

E

G

T

F

T

S

D

L

S

K

Q

M

E

Hydrophobic

Polar

Positive

Negative

Mechanism of Action

The mechanisms of retatrutide are well-characterized through Phase 2/3 clinical trials and preclinical studies. It is the first triple GIP/GLP-1/Glucagon receptor agonist in late-stage development.

How It Works (Simplified)

Retatrutide activates three hormone receptors simultaneously, providing comprehensive metabolic effects:

Scientific Pathways

Triple Receptor Signaling Cascade (Metabolic Effects)

Retatrutide Administration
    ↓
├── GLP-1R PATHWAY
│   ├── Brain: Satiety ↑, hunger ↓
│   ├── Pancreas: Insulin ↑, glucagon ↓
│   └── GI: Gastric emptying delayed
│
├── GIPR PATHWAY
│   ├── Pancreas: Additional insulin secretion
│   ├── Adipose: Healthy adipocyte function
│   └── Brain: Enhanced satiety integration
│
└── GCGR PATHWAY
    ├── Liver: Fat oxidation ↑, steatosis ↓
    ├── Brown fat: Thermogenesis ↑
    └── Energy expenditure: 10-15% increase

Hepatic Glucagon Pathway (Liver-Specific Effects)

Glucagon Receptor Activation → Liver (rich in GCGR)
    ↓
├── ↑ Hepatic lipid oxidation
├── ↓ Lipogenesis (fat creation)
├── ↓ Oxidative stress in mitochondria
└── Anti-fibrotic benefits → MASLD improvement

Key Research: Jastreboff AM et al. (2023) demonstrated 24.2% weight loss at 48 weeks in Phase 2. PMID:37366315

Important Limitations

• Retatrutide is an investigational drug not yet approved by FDA/EMA
• Long-term safety beyond 68 weeks is still being evaluated in Phase 3 trials
• Cardiovascular and kidney outcomes data pending (TRIUMPH-Outcomes ongoing)
• Head-to-head comparison to tirzepatide results pending (TRIUMPH-5 ongoing)
• Not available outside clinical trials; any other source is illegitimate

Evidence-Chained Benefits

Evidence-Chained Benefits

Research findings linked to mechanisms and clinical outcomes

4 chains

Mechanism Triple receptor agonism (GIP/GLP-1/GCGR) reducing appetite and increasing energy expenditure

Established 15 direct studies

Benefit shown to induce significant weight loss

Evidence Level

High

5 Human

6 Animal

4 In Vitro

View 2 key findings

RCT Jastreboff AM et al. 2023 PMID:37366315

24.2% weight loss at 48 weeks with 12mg dose in Phase 2 obesity trial

RCT TRIUMPH-4 2025 PMID:41090431

28.7% weight loss at 68 weeks, 71.2 lbs average in Phase 3

Mechanism GLP-1/GIP-mediated insulin secretion enhancement and glucagon suppression

Established 8 direct studies

Benefit shown to improve glycemic control in type 2 diabetes

Evidence Level

High

3 Human

4 Animal

2 In Vitro

View 2 key findings

RCT Rosenstock J et al. 2023 PMID:37385280

HbA1c reduction of 2.02% with 82% achieving HbA1c ≤6.5% at 36 weeks

RCT Coskun T et al. 2022 PMID:36354040

Dose-dependent glycemic improvements in Phase 1b trial

Mechanism Glucagon receptor activation promoting hepatic lipid oxidation and reduced lipogenesis

Established 6 direct studies

Benefit shown to reduce liver fat in MASLD

Evidence Level

High

1 Human

4 Animal

2 In Vitro

View 2 key findings

RCT Sanyal AJ et al. 2024 PMID:38858523

81-82% liver fat reduction at 48 weeks, with 89-93% achieving normal liver fat levels

ANI Preclinical hepatic studies PMID:38858523

Improved hepatic oxidative phosphorylation and mitochondrial function

Mechanism GCGR-mediated thermogenesis in brown adipose tissue

Supported 4 direct studies

Benefit appears to increase energy expenditure

Evidence Level

Moderate

1 Human

4 Animal

2 In Vitro

View 2 key findings

ANI Preclinical metabolic studies PMID:36354040

Glucagon receptor activation increases thermogenesis and metabolic rate by 10-15%

RCT Body composition substudy 2025 PMID:40609566

Effects on body composition in T2D patients demonstrating preferential fat loss

Mechanism Confidence

Established

Supported

Emerging

Evidence Level

High

Moderate

Low

Very Low

What to Expect

Timeline based on observations from published studies. Individual responses may vary.

Week 1-4 PMID:37366315

Initial dose titration period. GI adaptation occurs as GLP-1 pathway activates. Appetite suppression begins within first week. Early weight loss typically 2-4% during titration phase.

Week 4-12 PMID:37366315

Continued dose escalation to maintenance dose. Weight loss accelerates as full triple receptor activation achieved. Average 8-12% weight loss by week 12 at higher doses. GI side effects typically improve.

Week 12-24 PMID:37385280

Sustained weight loss trajectory. Metabolic improvements measurable including HbA1c reductions in diabetic patients. Liver fat reduction substantial in those with MASLD. Weight loss reaches 15-18% range.

Week 24-48 PMID:37366315

Continued linear weight loss without plateau at 48 weeks in Phase 2 trials. Maximum observed weight loss of 24.2% at 48 weeks. Metabolic parameters continue to improve.

Week 48+ PMID:41090431

Phase 3 TRIUMPH-4 showed 28.7% weight loss at 68 weeks, suggesting continued efficacy beyond 48 weeks. Long-term maintenance data from TRIUMPH-6 (116 weeks) pending.

Research-Based Observations

This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.

Quality Checklist

Visual indicators to help evaluate Retatrutide product quality

Good Signs (6 indicators)

Investigational drug - only available through clinical trials

Manufactured by Eli Lilly under pharmaceutical GMP standards

Proper cold chain storage maintained in clinical settings

Administered under medical supervision in trials

Clear documentation of lot number and expiration

Pre-filled injection devices used in trials

Warning Signs (5 indicators)

Any product claiming to be retatrutide outside clinical trials

Research chemical suppliers claiming to sell retatrutide

Products without Eli Lilly manufacturing documentation

Unusually low pricing for an investigational compound

Claims of FDA approval (not yet approved as of 2026)

Bad Signs (6 indicators)

Any non-clinical-trial source of retatrutide

Lyophilized powder format (clinical formulation is liquid)

No verifiable chain of custody documentation

Products marketed for human use outside trials

Missing or fraudulent certificate of analysis

Any seller claiming legal retail availability

Positive quality indicator

Requires evaluation

Potential quality issue

For Research Evaluation Only

These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.

Peptide Interactions

Known and theoretical interactions when combining Retatrutide with other peptides. Based on published research and mechanistic considerations.

Synergistic

Compatible

Caution

Avoid

Ipamorelin

Compatible

Compatible

Non-overlapping mechanisms. Ipamorelin acts on ghrelin receptors while retatrutide targets incretin receptors. No known contraindications though combined effects on appetite are unstudied.

CJC-1295

Compatible

Compatible

Different pathways (GHRH vs incretin). Theoretical complementary metabolic benefits. No interaction studies available.

BPC-157

Caution

Caution

Both affect GI function. Retatrutide slows gastric emptying while BPC-157 is gastroprotective. Unclear if effects interact; monitor GI symptoms if combined.

AOD-9604

Caution

Caution

Both target metabolic and lipolytic pathways. Combined effects on fat metabolism are unstudied. Exercise caution due to potential additive effects.

Tirzepatide

Avoid

Avoid

Both are incretin-based therapies targeting overlapping receptors. Tirzepatide (GIP/GLP-1) and retatrutide (GIP/GLP-1/GCGR) should not be combined due to additive effects and increased risk of severe GI adverse events.

Semaglutide

Avoid

Avoid

Both activate GLP-1 receptors. Combining would cause excessive GLP-1 pathway stimulation with high risk of severe nausea, vomiting, and potentially dangerous hypoglycemia.

Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.

References

124 Sources

15 Human

6 Preclinical

Key Studies Cited

RCT Jastreboff AM et al. 2023

PMID:37366315

RCT TRIUMPH-4 2025

PMID:41090431

RCT Rosenstock J et al. 2023

PMID:37385280

RCT Coskun T et al. 2022

PMID:36354040

RCT Sanyal AJ et al. 2024

PMID:38858523

RCT Body composition substudy 2025

PMID:40609566

Full reference list available on request. All citations link to PubMed for verification.

Methodology Note

This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.

For complete methodology details, see our Methodology page.